Terug
Dagbereik
€ 2,25
€ 2,41
52-Weeksbereik
€ 2,25
€ 6,51
Volume
13.725.430
50D / 200D Gem.
€ 4,66
/
€ 4,80
Vorige Slotkoers
€ 2,44
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 120,3 | 0,3 |
| P/B | — | 2,9 |
| ROE % | — | 3,7 |
| Net Margin % | 1,7 | 3,8 |
| Rev Growth 5Y % | 46,7 | 10,0 |
| D/E | — | 0,2 |
Koersdoel Analisten
Hold
€ 9,00
+293.0%
Forward WPA
-€ 0,01
Omzet Sch.
470 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 0,42
€ 0,33 – € 0,46
|
730 M | 5 |
| FY2029 |
€ 0,20
€ 0,16 – € 0,22
|
600 M | 2 |
| FY2028 |
€ 0,10
-€ 0,12 – € 0,24
|
530 M | 7 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 1, 2026 |
HOOPER ANTHONY C
|
grant | 35.000 | € 3,27 | € 114.450 |
| Nov 11, 2025 |
Ahuja Ajay
Chief Medical Officer
|
grant | 318.200 | — | — |
| Jun 23, 2025 |
Marasco Dominic
Pres, Endocrine Business Unit
|
grant | 1.000.000 | — | — |
| May 19, 2025 |
Castagna Michael
Chief Executive Officer
|
other | 26.114 | € 4,37 | € 114.118 |
| May 14, 2025 |
Marasco Dominic
Pres, Endocrine Business Unit
|
grant | 153.929 | — | — |
| May 14, 2025 |
CONSIGLIO RONALD J
|
grant | 52.854 | — | — |
| May 14, 2025 |
Friedman Michael A
|
grant | 52.854 | — | — |
| May 14, 2025 |
MUNDKUR CHRISTINE
|
grant | 52.854 | — | — |
| May 14, 2025 |
Kay Sabrina
|
grant | 63.425 | — | — |
| May 14, 2025 |
Shannon James Samuel
|
grant | 52.854 | — | — |
| May 14, 2025 |
Grancio Jennifer
|
grant | 52.854 | — | — |
| May 14, 2025 |
HOOPER ANTHONY C
|
grant | 88.425 | € 4,56 | — |
| May 14, 2025 |
Binder Steven B.
|
grant | 52.854 | — | — |
| May 13, 2025 |
Prentiss Christopher B
Chief Financial Officer
|
grant | 264.000 | — | — |
| May 13, 2025 |
Singh Sanjay R
EVP Technical Operations
|
grant | 264.000 | — | — |
| May 13, 2025 |
Castagna Michael
Chief Executive Officer
|
grant | 951.000 | — | — |
| May 13, 2025 |
Tross Stuart A
Chief People & Workpl Officer
|
grant | 264.000 | — | — |
| May 13, 2025 |
Thomson David
EVP Genl Counsel & Secretary
|
sell | 32.179 | € 4,68 | € 150.598 |
| May 13, 2025 |
Thomson David
EVP Genl Counsel & Secretary
|
grant | 264.000 | — | — |
| May 13, 2025 |
Binder Steven B.
|
sell | 80.144 | € 4,69 | € 375.875 |
Belangrijkste Punten
Revenue grew 46,65% annually over 5 years — strong growth
Earnings declined -78,75% over the past year
Generating 13,69M in free cash flow
P/E of 120,34 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 24,42%
Cash machine — converts 233,48% of earnings into free cash flow
Groei
Revenue Growth (5Y)
46,65%
Revenue (1Y)22,23%
Earnings (1Y)-78,75%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC6,89%
Net Margin1,68%
Op. Margin11,12%
Veiligheid
Debt / Equity
N/A
Current Ratio1,70
Interest Coverage2,81
Waardering
P/E Ratio
120,34
P/B RatioN/A
EV/EBITDA28,45
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 22,23% | Revenue Growth (3Y) | 32,44% |
| Earnings Growth (1Y) | -78,75% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 46,65% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 348,97M | Net Income (TTM) | 5,86M |
| ROE | N/A | ROA | 0,74% |
| Gross Margin | 82,47% | Operating Margin | 11,12% |
| Net Margin | 1,68% | Free Cash Flow (TTM) | 13,69M |
| ROIC | 6,89% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1,70 |
| Interest Coverage | 2,81 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 120,34 | P/B Ratio | N/A |
| P/S Ratio | 2,02 | PEG Ratio | -3,69 |
| EV/EBITDA | 28,45 | Dividend Yield | 0,00% |
| Market Cap | 705,55M | Enterprise Value | 1,10B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 348,97M | 285,50M | 198,96M | 99,77M | 75,44M |
| Net Income | 5,86M | 27,59M | -11,94M | -87,40M | -80,93M |
| EPS (Diluted) | 0,02 | 0,10 | -0,04 | -0,44 | -0,37 |
| Gross Profit | 287,81M | 208,90M | 136,19M | 42,27M | 36,59M |
| Operating Income | 38,80M | 72,59M | 8,68M | -64,11M | -47,02M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 792,18M | 393,84M | 475,20M | 295,28M | 321,16M |
| Total Liabilities | 843,20M | 472,66M | 721,37M | 545,82M | 530,51M |
| Shareholders' Equity | -51,02M | -78,82M | -246,17M | -250,54M | -209,35M |
| Total Debt | 473,38M | 47,70M | 272,62M | 288,40M | 289,22M |
| Cash & Equivalents | 74,88M | 46,34M | 238,48M | 69,77M | 124,18M |
| Current Assets | 291,58M | 268,31M | 373,39M | 234,90M | 219,49M |
| Current Liabilities | 171,03M | 81,84M | 104,13M | 67,30M | 48,35M |